BOLD
Boundless Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.31
−1.28%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.38
From 52W high−23.00%
Volume219721.00
Market cap$53.38M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$2.38
From 52W high
−23.00%
Volume
219721.00
Market cap
$53.38M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
P/E (TTM)
—
RSI (14)
28.8
MomentumView details →
1D Return
−1.28%
YTD Return
+95.00%
SummaryUpdated Jun 1, 2026
Boundless Bio, Inc. (NASDAQ:BOLD) is a clinical-stage biotechnology company founded in 2018 and headquartered in San Diego, California. Originally incorporated as Pretzel Therapeutics, Inc., the company changed its name to Boundless Bio in July 2019 and went public in 2016. The company focuses on developing innovative cancer therapeutics specifically designed to treat patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a novel approach in oncology that addresses a previously underexplored mechanism of cancer drug resistance.
Similar companies
Latest newsMore news →
Boundless Bio, Inc. entered into Amendment No. 1 to its Agreement and Plan of Merger and Reorganization with Serapha Bio, Inc. and Boulder Merger Sub Corp. on August 28, 2026, clarifying provisions, adding mechanics for Serapha RSU conversion and pre-funded warrant issuance, and changing the voting standard for increasing authorized shares.52d agoSerapha Bio launched with a licensing deal from a Chinese drug company.118d agoBoundless Bio and Serapha Bio announced a concurrent private placement of $230 million.118d ago